
US-based VLP Therapeutics develops vaccines and targeted antibody agents for cancer and infectious diseases.
VLP Therapeutics, founded in Gaithersburg, United States, is a biopharmaceutical company dedicated to developing innovative vaccines and targeted antibody agents. Their core mission is to combat cancer and infectious diseases such as malaria, dengue fever, Zika virus-based diseases, and autoimmune disorders through next-generation therapeutic solutions. The company leverages advanced technologies like Surface Antigen Display and Interior Gene Delivery to create effective preventative and therapeutic vaccines.
Notable figures associated with VLP Therapeutics include its founders and an esteemed advisory board comprising experts in the field. The company has garnered attention for its significant achievements, including the development of a dengue vaccine that successfully induces antibodies and reduces replication. VLP Therapeutics' work has had a substantial impact on global health, positioning them as a key player in the fight against some of the world's most challenging diseases.

Voltron Therapeutics
voltrontx.com

Virion Therapeutics
viriontx.com

Novavax
novavax.com

Vaccinex
vaccinex.com

Arbovax

Globavir Biosciences

Solaris Vaccines
solarisvax.com

MalarVx
malarvx.com

VitriVax
vitrivaxbio.com

Vivaldi Biosciences

Precision Virologics

Uvax Bio
uvaxbio.com

Immunomic Therapeutics
immunomix.com

X-Vax Technology

Vir Biotechnology
vir.bio
Companies similar to VLP Therapeutics include Voltron Therapeutics, Virion Therapeutics, Novavax and Vaccinex.
VLP Therapeutics was founded in 2012.
VLP Therapeutics' headquarters is located in Gaithersburg, MD, US.
VLP Therapeutics' most recent funding round was for $21M (USD) in December 2021.
As of Dec 27, 2021, VLP Therapeutics has raised a total of $43.3M (USD).
VLP Therapeutics has 7 employees as of Feb 4, 2024.